drugset / Trial / NCT00688402

Study to Compare Different Formulations of AZD3355

NCT00688402

Phase 1 Completed 48 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of the study is to compare different formulations of AZD3355 in regard to possible adverse events such as sensations of numbness, tinglings and heat in the skin.

Timeline

Start
2008-04
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject lesogaberan Small molecule 65 mg
Subject lesogaberan Small molecule 150 mg